Pacific Edge Limited (PEB) has announced that it has completed a commercial agreement with Te Whatu Ora – Southern for the use of its non-invasive Cxbladder genomic biomarker tests.
The agreement, which was signed on the 21st July 2022, allows for the use of PEB's Cxbladder technology to detect and manage bladder cancer.
Cxbladder is a urine test that is optimized for the detection and management of bladder cancer and is reimbursed by the US Centers for Medicare & Medicaid Services (CMS) for use in the US.
It is also available for purchase in New Zealand.
See more
